8-chloro-3-(cyclopropylmethyl)-7-phenethoxy-[1,2,4]triazolo[4,3-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 8-chloro-3-(cyclopropylmethyl)-7-phenethoxy-[1,2,4]triazolo[4,3-a]pyridine
• 英文别名: 8-Chloro-3-(cyclopropylmethyl)-7-(2-phenylethoxy)-[1,2,4]triazolo[4,3-a]pyridine；8-chloro-3-(cyclopropylmethyl)-7-(2-phenylethoxy)-[1,2,4]triazolo[4,3-a]pyridine
• 化学式: C₁₈H₁₈ClN₃O
• 分子量: 327.813
• InChiKey: HUKLBCKGOFIXBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯乙醇 、 8-氯-3-(环丙基甲基)-7-碘-[1,2,4]三唑并[4,3-A]吡啶 在 copper(l) iodide 、 1,10-菲罗啉 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 17.0h， 以24%的产率得到8-chloro-3-(cyclopropylmethyl)-7-phenethoxy-[1,2,4]triazolo[4,3-a]pyridine
  参考文献：
  名称：

  Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia

  摘要：

  Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.11.018

文献信息

• [EN] TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS D'ÉTHER DE TRIAZOLOPYRIDINE ET LEUR UTILISATION CONTRE DES TROUBLES NEUROLOGIQUES ET PYSCHIATRIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015042243A1

  公开（公告）日：2015-03-26

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物调节mGluR2受体，可能有助于治疗中枢神经系统的各种疾病。
• TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160237081A1

  公开（公告）日：2016-08-18

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.

  本公开涉及公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物调节mGluR2受体，可能有助于治疗各种中枢神经系统的疾病。
• US9738642B2
  申请人：——

  公开号：US9738642B2

  公开（公告）日：2017-08-22
• Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
  作者：Mendi A. Higgins、Lawrence R. Marcin、F. Christopher Zusi、Robert Gentles、Min Ding、Bradley C. Pearce、Amy Easton、Walter A. Kostich、Matthew A. Seager、Clotilde Bourin、Linda J. Bristow、Kim A. Johnson、Regina Miller、John Hogan、Valerie Whiterock、Michael Gulianello、Meredith Ferrante、Yanling Huang、Adam Hendricson、Andrew Alt、John E. Macor、Joanne J. Bronson

  DOI：10.1016/j.bmc.2016.11.018

  日期：2017.1

  Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.